2197 — Clover Biopharmaceuticals Balance Sheet
0.000.00%
- HK$271.09m
- -HK$88.62m
- CNY38.42m
Annual balance sheet for Clover Biopharmaceuticals, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | PROSPECTUS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 807 | 2,866 | 1,641 | 766 | 428 |
Net Total Accounts Receivable | |||||
Net Total Receivables | — | 99.6 | 43.4 | 62 | 53.5 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 1,048 | 5,076 | 4,390 | 1,900 | 663 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 87 | 222 | 242 | 162 | 116 |
Net Intangible Assets | |||||
Other Long Term Assets | |||||
Total Assets | 1,188 | 5,346 | 4,695 | 2,101 | 813 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 66.7 | 2,148 | 2,829 | 2,277 | 1,908 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Liabilities | 2,170 | 4,127 | 5,363 | 2,834 | 2,449 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Treasury Stock | |||||
Other Equity | |||||
Total Equity | -983 | 1,219 | -668 | -733 | -1,636 |
Total Liabilities & Shareholders' Equity | 1,188 | 5,346 | 4,695 | 2,101 | 813 |
Total Common Shares Outstanding |